Current Report Filing (8-k)
January 10 2023 - 4:03PM
Edgar (US Regulatory)
0001810560false0001810560revb:CommonStockParValue0001PerShareMember2023-01-102023-01-100001810560revb:UnitsEachConsistingOfOneShareOfCommonStockAndOneRedeemableWarrantMember2023-01-102023-01-100001810560revb:RedeemableWarrantsEachExercisableForShareOfCommonStockAtExercisePriceOf1150PerShareMember2023-01-102023-01-1000018105602023-01-102023-01-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of earliest event reported): January 10, 2023 |
REVELATION BIOSCIENCES, INC.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
Delaware |
001-39603 |
84-3898466 |
(State or Other Jurisdiction
of Incorporation) |
(Commission File Number) |
(IRS Employer
Identification No.) |
|
|
|
|
|
4660 La Jolla Village Drive Suite 100 |
|
San Diego, California |
|
92122 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
Registrant’s Telephone Number, Including Area Code: (650) 800-3717 |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
Symbol(s) |
|
Name of each exchange on which registered
|
Units, each consisting of one share of common stock and one redeemable warrant |
|
REVBU |
|
The NASDAQ Stock Market LLC |
Common stock, par value $0.001 per share |
|
REVB |
|
The NASDAQ Stock Market LLC |
Redeemable warrants, each exercisable for a share of common stock at an exercise price of $11.50 per share |
|
REVBW |
|
The NASDAQ Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events
On January 10, 2023, Revelation Biosciences, Inc. (the “Company”) issued a press release, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K, announcing that, on January 13, 2023, the Company’s units, which trade with the ticker symbol “REVBU” will be mandatorily separated and the units will no longer trade on the Nasdaq Capital Market. Each unit is comprised of one share of the Company’s common stock and one warrant that entitles the holder to purchase one share of common stock at price of $11.50 per share. In the separation, unit owners will receive the number of shares of common stock and warrants underlying such units. This is a mandatory and automatic separation, and no action is required by the holders of units.
The common stock and warrants are listed on the Nasdaq Capital Market and trade with the ticker symbols “REVB” and “REVBW”, respectively.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
REVELATION BIOSCIENCES, INC. |
|
|
|
|
Date: |
January 10, 2023 |
By: |
/s/ Chester S. Zygmont, III |
|
|
|
Chester S. Zygmont, III
Chief Financial Officer
(principal financial and accounting officer)
|
Petra Acquisition (NASDAQ:PAIC)
Historical Stock Chart
From Oct 2024 to Nov 2024
Petra Acquisition (NASDAQ:PAIC)
Historical Stock Chart
From Nov 2023 to Nov 2024
